A number of biopharmaceutical companies to fight the capital market cancer early screening or into the next capital pool?

On February 5, Beckon Medical announced that it would issue 66.667 million shares at a price of HK$27.36 per share, with a net proceeds estimated at about HK$1,716.7 million.
500 shares per share and is expected to go public on February 8, 2021.
hong Kong offering shares initially offered under the Hong Kong public offering were substantially oversubscribed, equivalent to about 402.8 times the initial hong Kong offering under the Hong Kong public offering.
, China Antibody's proposed HK$110 million sale of its interest in china's healthcare fund, was announced on February 5, 2021, and on February 4, 2021, the company and its buyer, Dragon Capital Opportunities SPC, on behalf of its name, Dragon, Capital SpecialItys 2 SP's independent portfolio) signed a contract under which the Company will sell its Class A participation shares in china Healthcare Fund 775347.912 units to the buyer at a cost of HK$110572365.73.
estimates that the Group will record unaudited earnings of approximately HK$3257,2365.73 from the sale, equivalent to a return on investment of about 41.76 per cent.
sale will be completed on 18 February 2021.
4th, Micro-Creative Heart Medical Technology Co., Ltd. was successfully listed on the main board of the Hong Kong Stock Exchange under the stock code "2160.HK".
Group Co., Ltd., a wholly-owned subsidiary of The Company, invested US$5 million to hold 3177,000 shares of Heartcom Medical.
On February 4, Haihe Pharmaceuticals filed an IPO application with The Shanghai Stock Exchange, according to a public announcement by the Shanghai Stock Exchange, haihe Pharmaceuticals has submitted an IPO application to the Company and was accepted on February 3.
according to the prospectus, Haihe Pharmaceuticals this time adopted the fifth set of listing standards of the board, the number of shares to be issued publicly does not exceed 221 million shares, the plan is to raise 3.15 billion yuan.
on the evening of February 3rd, China Biopharmaceuticals announced that its board of directors had approved preliminary proposals for a possible RMB share issue and listing on the Shanghai Stock Exchange.
domestic issues are subject to market conditions, shareholder approval at the Company's general meeting of shareholders, and necessary regulatory approval.
(Gan Li Pharmaceuticals CDK 4/6 Inhibitors Qualified by FDA Fast Track) On February 1, Gan Li Pharmaceuticals announced that the FDA has granted it fast-track qualification for CDK4/6 inhibitors for the treatment of glioblastoma patients.
noted that the drug was approved by the FDA last year as an orphan drug for the treatment of malignant gliomas.
.
the first U.S. listing application for Terripley monoantigen will be filed with the FDA this year for nasopharyngeal cancer treatment, according to a press release.
Astellas leukaemia new drug "Gilantini" approved in China, February 1, China's State Drug Administration (NMPA) official website of the latest public announcement, Astellas Fuma acid ji Xospata, gilteritinib's listing application status in China has been updated to "approval completed - pending certification", the drug approval number is: national drug code HJ20210009.
means the clinically urgent need for new drugs to be approved in China.
according to the NMPA Drug Review Center (CDE), the application is intended to treat adult patients with recurring or incurable acute myeloid leukemia (AML) with FLT3 mutations.
February 1st, the latest announcement on the HKEx website showed that SciClone Pharmaceuticals' IPO application had been heard by hkEx.
Pharmaceuticals filed an IPO application on the Hong Kong Stock Exchange in September 2020 under Section 8.12 of the Listing Rules, with the co-sponsors being COG, Morgan Stanley and Credit Suisse (Hong Kong).
the HKEx IPO will be used primarily to acquire or authorize the introduction of new drug candidates, as well as to promote the development and commercialization of clinical phase candidates.
On January 31st, Greenlee Pharmaceuticals announced that it had signed a contract with Hillhouse NEV, a fund owned by High Leaf Capital, to obtain HK$1.25 billion in financing from High Capital through a targeted new issue, which was a 10% premium to the closing price on the date of the agreement.
addition, Tsing Ting Capital also received the issued shares of the approved Greenlee Pharmaceuticals at the same price per share.
press release, the total value of the two transactions is HK$2.4 billion, and after the completion of the transaction, Gao Will Capital will hold a 15.60% stake in Greenlee Pharmaceuticals.
January 30, the Shanghai Stock Exchange Science and Trot Board public information shows that Baiji Shenzhou has submitted an IPO application to the Science and Trot Board, and on January 29 was accepted.
according to the prospectines, Baiji Shenzhou's joint sponsor (the main underwriter) for the listing of COG and Goldman Sachs, the proposed capital of 20 billion yuan.
it is worth mentioning that Baiji Shenzhou was listed on the NASDAQ Exchange in 2016 and landed on the Hong Kong Stock Exchange in 2018.
the IPO on the Board means that Baiji Shenzhou is expected to become a listed biopharmaceutical company on NASDAQ, HKEx and Kotseng Board.
(International News) - Johnson and Johnson has filed an application with the FDA for emergency use of a single dose of the new crown vaccine, and Johnson and Johnson announced today that its Janssen corporation has filed an application with the FDA seeking an emergency use authorization (EUA) for a single dose of the new crown vaccine.
EUA application submission is based on overall effectiveness and safety data for Phase 3 clinical trial ENSEMBLE, where a single dose of the vaccine reaches all major and critical secondary endpoints of the trial.
(Xinhua) -- The U.S. FDA has accelerated approval of the export of oral MET inhibitor Tepotinib (tepotinib) for the treatment of adult patients with metastasis non-small cell lung cancer (NSCLC) with a jump variant of MET Exon 14 (METex14), Merck KGaA's EMD Serono announced on February 4.
150 million euros to develop next-generation mRNA new crown vaccine, GlaxoSmithKline and Cure, February 4 Vac announced that the two sides will build on the existing cooperation, a new 150 million euro cooperation to jointly develop the next generation of mRNA new crown vaccine, it has the potential to use multi-price vaccine strategy in one vaccine to provide protection against multiple new coronary mutant strains.
(Bayer) Innovative Therapy Listing Application was accepted by CDE on February 3rd, the latest announcement from the Drug Review Center (CDE) of the State Drug Administration of China, and Bayer's application for the listing of innovative therapy finerenone films in China was accepted by CDE.
public information, finerenone is a potential "first-in-class" nonsteroidal selective salt corticosteroid-inhibitor antagonist (MRA).
( ) On February 2nd , The Company announced the acquisition of the Couvet production base in Switzerland , and the company announced today that It will acquire the production base of Couvet , Switzerland .
Pharmaceuticals is the world's leading new drug research and development and production CDMO enterprises, after the acquisition, the Covey plant will become the company's first production base in Europe, further expand its platform capacity and scale, help partners accelerate the development process of new drugs for the benefit of patients around the world.
Horizon's proposed acquisition of Vila Bio on February 2nd, Therapeutics and Vila Bio announced that they had reached an agreement to buy Vila Bio for about $3.05bn.
Horizon will harvest Vila Bio's approved anti-CD19 monoclonal antibody Uplizna (inebilizumab-cdon) for the treatment of optic neurospinal cord disease (NMOSD), the development of several in-research therapies in the pipeline, and Vila Bio's scientific expertise in autoimmune diseases and deep experience in the development of biological products.
.785 million to build HIV healing therapy, Gilead Sciences and Grytstone Oncology announced on February 2nd that they have reached a partnership and licensing agreement to develop a vaccine-based immunotherapy to support Gilead's efforts to discover CUREs for HIV infection.
Gilead Sciences and Grytstone will use Gridstone's proprietary vaccine platform to develop HIV-specific therapeutic vaccines, consisting of self-amplified mRNA (SAM) and adenovirus vectors, and antigens developed by Gilead Sciences.
(Weekly Financing) (Oriental Kaiyin Completes $23 Million C1 Round of Financing) On February 5, Oriental Qiyin, the leading children's speech rehabilitation and autism intervention agency in China, announced the completion of the C1 round of $23 million financing.
this round of financing led by Chiba Capital, old shareholders Northern Lights Venture Capital, Changling Capital and other continuous addition, Thai Capital as the exclusive financial adviser.
this round of financing will be used for the expansion of direct-to-the-center, evidence-based medical-based system product development and clinical research, online service system construction, rehabilitation therapist training system to further improve.
on February 5th, Wan multiplier gene completed tens of millions of dollars of Pre-A round financing, focusing on the development of high-volume single-cell sequencing overall solution, announced the completion of tens of millions of yuan of Pre-A round financing, with exclusive investment from Northern Lights Ventures.
This round of financing will be mainly used for the marketing of liquid microflow-controlled single-cell sequencer and its supporting multi-group reagents developed by Wan multiplier gene, and expand the scope of high-volume single-cell sequencing services.
million multiplier gene adopts the more convenient operation, equipment function and reagent expansion of the droplet microflow control technology, to create an international advanced high-volume single-cell multi-group technology multi-group gene platform.
On February 5th, Beijing Yingfei Zhi Pharmaceutical Technology Co., Ltd. announced that it had received the Pre-A round of investment from Lizhu Pharmaceutical Equity Investment Management Co., Ltd., a wholist-owned investment platform of Lizhu Pharmaceuticals in Zhuhai. The financing will be used to upgrade teams, improve smart drug research and development systems and expand research and development pipelines to better serve pharmaceutical companies, biotechnology companies and partners around the world, said Dr. Jianfeng Yan, founder of
Yingfei Zhi Pharmaceuticals.
Million Multiplier Gene was financed by Northern Lights Ventures on February 5th, focusing on the development of a holistic solution for high-volume single-cell sequencing, and announced the completion of tens of millions of dollars of Pre-A round financing, with exclusive investment from Northern Lights Ventures.
It is understood that this round of financing will be mainly used for the independent development of the wanding gene liquid microflow control single-cell sequencer and its supporting multi-group learning reagents marketing, and expand the scope of high-volume single-cell sequencing services.
February 4th, The Good Pregnancy Gang, a chain focused on infertility, completed a new round of financing led by Songyu Capital.
the current round of financing will be used to continue to enhance the reproductive specialist medical capacity, build more sub-disease management system, the introduction and development of medical professional team personnel.
4th, Guangzhou Microyuan Gene Technology Co., Ltd. announced the completion of 200 million yuan C round of financing.
this round of financing is led by Tencent, with the participation of existing shareholders such as CHINA Capital, Dingyi Investment, Guoke Jia and others.
this is a new round of financing within six months after micro-gene completed the 200 million yuan B round of financing in August 2020.
round of financing will continue to focus on product development and upgrading, medical device product registration, strengthening medical brand marketing and clinical services and other strategic direction.
On February 2nd, neoX Biotech, a cutting-edge technology company that calculates the design-driven research and development of new drugs, announced the completion of a $30 million round of A-round financing, jointly led by Yunyu Capital and Five Source Capital, BAI Capital, Xiangfeng Investment and Investment, and the existing investors Yuanyu Capital and Sequoia China continued to add code.
this round of financing will be mainly used to accelerate the company's multi-innovation drug pipeline preclinical development, expand talent team building, and expand international business cooperation.
(Nobo Medical Completes Round B Billions of Dollars Financing) On February 2, Shenzhen Nobo Medical Technology Co., Ltd., the leading provider of software and hardware integrated solutions for smart hospitals based on the Internet of Things, announced the completion of hundreds of millions of yuan B rounds of financing.
this round of financing led by Saifu Asia Investment Fund, Shenzhen High-new Investment, Jiaming Haochun, Yi Feit and Investment.
round of financing will be mainly used for the company's existing product iteration upgrade and expansion of new product lines, high-tech research and development talent introduction, domestic and foreign market development and sales network upgrade.
, Wuhan Emison Life Technology Co., Ltd. announced the completion of nearly 100 million yuan B round of financing, by the deep-ploughed medical and health sector